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Abstract 
Glutamate receptors sensitive to N-methyl-D-aspartate (NMDA) are important in early 
brain development, influencing cell proliferation and migration, neuritogenesis, axon 
guidance and synapse formation. The kynurenine pathway of tryptophan metabolism 
includes an agonist (quinolinic acid) and an antagonist (kynurenic acid) at these receptors. 
Rats were treated in late gestation with 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-
benzene-sulphonamide (Ro61-8048), an inhibitor of kynurenine-3-monoxygenase which 
diverts kynurenine metabolism to kynurenic acid. Within 5h of drug administration there 
was a significant decrease in GluN2A expression and increased GluN2B in the embryo 
brains, with changes in sonic hedgehog at 24h. When injected dams were allowed to litter 
normally, the brains of offspring were removed at postnatal day 21 (P21). Recordings of 
hippocampal field excitatory synaptic potentials (fEPSPs) showed that prenatal exposure 
to Ro61-8048 increased neuronal excitability and paired-pulse facilitation. Long-term 
potentiation was also increased, with no change in long-term depression. At this time, 
levels of GluN2A, GluN2B and postsynaptic density protein PSD-95 were all increased. 
Among several neurodevelopmental proteins, the expression of sonic hedgehog was 
increased, but DISC1 and dependence receptors were unaffected, while raised levels of 
doublecortin and Proliferating Cell Nuclear Antigen (PCNA) suggested increased 
neurogenesis. The results reveal that inhibiting the kynurenine pathway in utero leads to 
molecular and functional synaptic changes in the embryos and offspring, indicating that the 
pathway is active during gestation and plays a significant role in the normal early 
development of the embryonic and neonatal nervous system. 
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1.  Introduction 
     Receptors for glutamate, especially NMDA receptors, are intimately involved in the 
early formation of the central nervous system (CNS), being required for neuronal migration 
(Komuro and Rakic, 1993; Behar et al., 1999), axonal and neurite growth in the foetus and 
postnatally, neurite extension and branching (Heng et al. 1999; Cuppini et al. 1999; Rajan 
and Cline 1998), spine formation and stability (Alvarez et al., 2007; Ultanir et al., 2007), the 
formation and stability of synapses (Colonnese et al., 2005) and neuronal plasticity 
(Fagiolini et al,. 2003; Iwasato et al., 2000). In rodents, NMDA receptor blockade during 
late foetal or early postnatal life also provokes a substantial loss or disruption of synapses 
compared with control animals (Dikranian et al., 2001; Ikonomidou et al., 1999; Harris et 
al.,  2003), partly mediated by the p53 tumour suppressor gene whose expression is 
controlled by NMDA receptors (Poulakie et al., 1999). The neuronal loss produces 
profound abnormalities of neuronal development, brain structure and behaviour 
reminiscent of those seen in schizophrenia (Harris et al., 2003; du Bois and Huang, 2007). 
In humans, a similar neuron loss occurs from the sixth month in utero until the third year of 
life, making it potentially susceptible to external modification and thus a potential source of 
pathology and of therapeutic intervention.  
    The use of extraneous compounds activating or blocking NMDA receptors, however, 
does not provide any indication of whether there is any natural, physiological system which 
normally regulates activity of these receptors by modulating the levels of endogenous 
agonists, antagonists or transduction systems. Such a pathway could modify the activation 
of NMDA receptors in response to external agents or events. One endogenous pathway 
which is known to include compounds capable of modifying NMDA receptor function is the 
kynurenine pathway of tryptophan oxidative metabolism (Stone, 1993, 2001; Stone and 
Darlington, 2002). This pathway - the major route of tryptophan metabolism - includes 
quinolinic acid, an agonist at NMDARs (Stone and Perkins, 1981) and kynurenic acid 
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which is an antagonist at all ionotropic glutamate receptors, though with greatest potency 
at NMDARs (Perkins and Stone, 1982) and with some ability to block nicotinic receptors in 
the CNS (Hilmas et al., 2001; Stone, 2007). The ratio between the levels of quinolinic acid 
and kynurenic acid is known to influence overall neuronal excitability (Scharfman et al., 
1999) and survival after CNS interventions (Boegman et al., 1985; Clark et al., 2005; 
Rodgers et al., 2010) when their levels are altered acutely in adult animals. This ratio can 
be modified by inhibiting kynurenine-3-monoxygenase (KMO)(Cozzi et al., 1999; Chiarugi 
et al., 2001; Chiarugi and Moroni, 1999; Clark et al., 2005; Zwilling et al., 2012). 
   Since the kynurenine pathway is potentially able to modulate NMDA receptor function 
and those receptors are important in neural development, this study was designed to 
address the question of whether the normal, physiological activity of the kynurenine 
pathway plays any role in brain development. The pathway has been inhibited using  
the KMO inhibitor 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-benzene-sulphonamide 
(Ro61-8048) (Rover et al., 1997), which has been administered to gestating female rats 
and the effects have been examined on the expression of proteins in the CNS of the 
embryos and neonates. The target molecules examined play key roles in neuronal 
development, neurite outgrowth, synapse formation and neurotransmitter release. They 
include components of synaptic vesicle and neurotransmitter release machinery and 
structural proteins associated with formation of the cytoskeleton. Several markers of axon 
guidance and synapse formation are included, as well as Nuclear Factor kappa B (NFkB) 
and cyclo-oxygenase 2 (COX-2). Since metabolites of the kynurenine pathway modulate 
the activity of NMDA receptors, the proteins examined include the NMDA receptor 
subunits, and the Postsynaptic Density Protein-95 (PSD-95). Finally, the neuronal 
maturation molecule doublecortin and the cell proliferation indicator Proliferating Cell 
Nuclear Antigen (PCNA) were included. 
 5 
     Protein expression was examined in embryos 5 and 24 hours after the administration of 
Ro61-8048 and in the brains of offspring at 21 days of age (P21), the time of weaning. The 
data reveal immediate effects of kynurenine pathway inhibition on NMDA receptor 
expression with additional, substantial changes at P21 in the expression of several 
proteins of importance to brain development. An electrophysiological examination of 
neuronal excitability and plasticity in the hippocampus indicates there are also significant 
functional differences between drug-treated and control animals. The results imply that the 
kynurenine pathway is of fundamental importance in early brain development. 
 
 
2.  Results 
2.1   HPLC analysis of kynurenines 
     The ability of Ro61-8048 to inhibit KMO in pregnant animals was confirmed using 
HPLC. Levels of kynurenic acid were increased 100-fold in the maternal plasma after 5h 
and from undetectable concentrations to 13pmols/g wet weight in the maternal brain (Fig. 
1B). Comparable, substantial, increases were seen in the brains of the embryos.  After 
24h, kynurenine and kynurenic acid concentrations had decreased to basal levels in the 
maternal brain, although they remained significantly elevated in the embryonic brains (Fig. 
1B). 
     At P21, there were no differences in the levels of tryptophan, kynurenine or kynurenic 
acid between pups born to dams treated with Ro61-8048 and those receiving vehicle (data 
not shown). Thus, the neurochemical and electrophysiological changes observed at P21 
are likely to be the result of interference with brain development around the time of the 
injections in utero, rather than any long-term effects of Ro61-8048 on tryptophan 
metabolism persisting at P21.  
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2.2   Effects of prenatal Ro61-8048 on embryonic brains during gestation 
     In the embryo brains, 5h and 24h after maternal administration of Ro61-8048, the 
expression was examined of the NMDA receptor subunits GluN1, GluN2A and GluN2B, as 
well as COX-2, NFkB, PCNA, SHH, Sox-2, EphA4, actin and PSD-95. There were no 
significant changes in the levels of most of these proteins or in the expression of the 
ubiquitous GluN1 subunit of NMDA receptors. However substantial, significant, changes 
were induced by 5h in both of the NMDA receptor subunits GluN2A and GluN2B, with a 
43% reduction of GluN2A and a 395% increase in the level of GluN2B (Fig. 2A). There 
were also significant increases in expression of the morphogenetic protein sonic hedgehog 
and NFkB after 24h (Fig. 2B). 
 
2.3   Effects of prenatal Ro61-8048 in P21 neonates 
2.3.1  Hippocampal function 
   Field excitatory postsynaptic potentials (fEPSPs) in the stratum radiatum and population 
spikes in stratum pyramidale were evoked to assess neuronal excitability and synaptic 
transmission (Fig. 3). Stimulus strength was increased until the fEPSP began to show 
signs of a population spike. The slices from animals treated with Ro61-8048 were more 
excitable than slices from control animals (ANOVA, F = 53.19, P < 0.0001, n = 16 controls, 
15 treated) with 3 individual points significantly different (Bonferroni test for multiple 
comparisons) (Fig. 3A).  A similar result was obtained using population spike amplitude, 
with a significant increase in Ro61-8048-exposed slices at corresponding current 
intensities (ANOVA, F = 73.84, P < 0.0001, n = 12), with 3 individual points significantly 
different (Fig. 3B).  
    Paired-pulse facilitation (PPF) and paired-pulse inhibition (PPI) were examined using 
stimulus pairs with interpulse intervals from 100ms to 10ms. There was a tendency for 
greater PPF in slices from drug-exposed animals (ANOVA, F = 4.4, P = 0.0004, n = 10 
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controls, 12 treated) (Fig. 3C) but there were no significant differences between individual 
points (Bonferroni test). A similar trend was apparent using population spikes (ANOVA, F = 
10.81, P < 0.0001) but with no significant differences between individual points (Fig. 3D). 
The effect of the rate at which stimulus pairs are presented was also examined as the rate 
was increased from 0.1Hz to 1Hz (Fig. 3E). No differences were seen between treated and 
control slices at presentation rates of 0.1, 0.2, or 0.5Hz, but at 0.5Hz or greater paired-
pulse effects in control slices changed from PPF to PPI (Fig. 3E). In contrast PPF was 
observed at all presentation rates in Ro61-8048-exposed slices, leading to significant 
differences between the slices (ANOVA, F = 21.32, P < 0.0001, with significant differences 
at 0.5 (P < 0.01) and 1Hz (P < 0.001) presentation.  
   Long-term potentiation (LTP) was induced using a burst of theta stimulation (5 bursts per 
second, for 2 seconds, of 4 stimuli delivered at 100Hz) (Larson et al. 1986). In control 
slices this increased fEPSP amplitude which reached a plateau after approximately 20min 
and was stable until the end of the recording period (Fig. 4A-C). A comparison of fEPSP 
size over the 5min before stimulation and the final 5min after theta stimulation showed a 
significant difference (ANOVA, F = 8.76; P < 0.0001, n = 5) with an increase of 28.2% 
between mean fEPSP slopes before and after LTP induction (P < 0.0001, paired t test, n = 
5).   
     For slices prepared from animals exposed to Ro61-8048 administration in utero, LTP 
was obtained with a similar time course but a higher magnitude than in control slices (Fig. 
4A). The fEPSP slopes were significantly greater than the corresponding pre-stimulation 
level (ANOVA, F = 41.25; P < 0.0001, n = 5) with an increase of 46.4% between the mean 
fEPSP slope before and after theta stimulation (P = 0.002, paired t test, n = 5). This LTP 
was significantly larger in treated animals compared with controls (ANOVA, F = 9.10, P < 
0.0001, n = 5), with significant differences (P < 0.01) for each of the final 5 time points (Fig. 
4A). 
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   Long-term depression (LTD) was induced using our published protocol (Forrest et al. 
2011) of trains of 3 pulses at 200Hz delivered every second for 5mins (stim1, Fig. 4D-F), 
repeated 20mins later (stim2). In slices from control animals, LTD was obtained in which 
the fEPSP slope between 25-30min after stim2 was very significantly lower than in the 
5min baseline period preceding stim1 (ANOVA, F = 4.60, P = 0.0003, n = 5), with a 
reduction of 19.8% between the fEPSP immediately preceding stim1 and at the end of 
recording (P < 0.0001, n = 5) (Fig. 4D). Slices from animals exposed to Ro61-8048 
showed a similar degree of LTD (F = 6.84, P < 0.0001, n = 5) with a reduction of fEPSP 
slope by 24.7% between the potentials before and after stimulation (P < 0.0001, n = 5) 
(Fig. 4D). The level of LTD produced in control and drug-exposed slices was not 
significantly different over the final 5 minutes (F = 0.20, P = 0.99). 
 
2.3.2.  Protein expression 
     In addition to the expression of proteins studied for the acute response to Ro61-8048 in  
embryos, the levels were examined of the synaptic vesicle release proteins synaptophysin, 
synaptotagmin and Vesicle Associated Membrane Protein-1 (VAMP-1; synaptobrevin), the 
small molecular weight GTPases RhoA and RhoB, the axonal guidance and contact 
determinants Unc5H1, Unc5H3, EphA4 and Deleted in Colorectal Cancer (DCC), tyrosine 
hydroxylase (TH), -synuclein, Disrupted in Schizophrenia-1 (DISC1), the 5HT2c receptor 
and  proteins associated with neuronal proliferation (PCNA and doublecortin). 
 
2.3.3.  Synaptic proteins 
     Levels of the GluN1 subunit of the NMDA receptor were not significantly different in 
animals exposed in utero to Ro61-8048 compared with controls (p = 0.49, Fig. 5), but 
there were significant differences in expression of the GluN2 subunits. Both the GluN2A (p 
= 0.004), and the GluN2B subunits (p = 0.03) were increased in the test animals relative to 
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controls (Fig. 5). There was also a significantly increased level of the post-synaptic density 
protein PSD-95, which is part of the post-synaptic protein complex which includes the 
NMDA receptor combinations (p = 0.03, Fig. 5).  
   Of the various proteins associated with synaptic vesicle release, synaptophysin showed 
a trend towards increased expression (p = 0.09) while synaptotagmin, a putative calcium 
sensor for vesicular release, and synaptobrevin (Vesicle Associated Membrane Protein-1; 
VAMP-1) did not show any differences between control and treated animals (p = 0.33, p = 
0.57 respectively). 
 
2.3.4.  Structural proteins 
     The two small GTPase enzymes RhoA and RhoB were examined since they have been 
shown to modulate or contribute to plastic changes induced electrophysiologically in the 
hippocampus (O’Kane et al. 2003a,b; McNair et al., 2010). Their activity is closely related 
to functions of NMDA receptors and they also play major roles in the regulation of 
cytoskeletal proteins. While there was no significant difference in the levels of RhoA 
between test and control pups (p = 0.94), there was a highly significant decrease in the 
expression of RhoB (p = 0.003, Fig. 5). 
 
2.3.5.   Developmental molecules 
     Since the hypothesis underlying this work was that disturbance of the kynurenine 
pathway in utero would change the expression or function of molecules responsible for 
early neuronal migration, axon guidance or synapse formation, the levels of several 
proteins with well characterised roles in these processes were examined. Levels of two 
major dependence receptors - the unc5H1 and unc5H3 proteins - showed no change in 
the Ro61-treated animals (p = 0.52, p = 0.87 respectively). Expression of the EphA4 
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receptor for secreted ephrin molecules was unchanged in the treated pups (p = 0.96) (data 
not shown). 
     Proliferating Cell Nuclear Antigen (PCNA), a protein often studied as a marker of the 
earliest phases of DNA synthesis which precede cell division and neurogenesis in the 
brain, was more highly expressed in the treated animals compared with controls (p = 0.02, 
Fig. 6). Similarly, expression of doublecortin, a molecule linked particularly with 
neurogenesis and the early stages of neuronal migration was significantly increased in the 
brains of pups exposed to Ro61-8048 (p = 0.03, Fig. 6). The sonic hedgehog protein 
(SHH), which is intimately involved in the polarisation and orientation of tissues and cell 
growth, was reduced to a significant extent after exposure to Ro61-8048 (p = 0.017, Fig. 6) 
while levels of the Sox-2 protein were unchanged (p = 0.45, data not shown).  
 
2.3.6.   Catecholamine-related proteins 
     Development of dopaminergic neurons is of particular interest in the understanding and 
possible prevention of the ‘neurodevelopmental disorders’ of schizophrenia and autism as 
well as neurodegenerative disorders such as Parkinson’s disease. The levels were 
examined of several molecules with a particular relevance to the development or function 
of dopaminergic neurons. These included tyrosine hydroxylase (TH), the initial enzyme in 
the conversion of dietary tyrosine to catecholamines.  The mean level of expression of TH 
was only 60% of that in control animals, but this difference did not reach statistical 
significance (p = 0.18, Fig. 6).  
     It has been claimed that levels of α-synuclein are increased in neurons of the 
nigrostriatal pathway of patients with Parkinson's disease, a disorder attributed to 
degeneration of the pathway. The aggregation of -synuclein can cause neuronal 
degeneration and any factor which alters its expression might have a corresponding 
facilitatory or inhibitory effect upon susceptibility to Parkinson's disease. In this study, 
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Ro61-8048 did not modify the levels of α-synuclein in the P21 rat hemispheres (p = 0.31, 
Fig. 6).  
   Two other molecules linked with dopaminergic function are Disrupted in Schizophrenia-1 
(DISC1) and the 5HT2C receptor. Levels of the former are reduced in patients with 
schizophrenia while the 5HT2C receptor is believed to exert an important modulating 
influence on the activity of neurons in the ventral tegmental mesolimbic pathway, and of 
their release of dopamine. The expression of both these proteins was unaffected after 
exposure to Ro61-8048 (DISC1: p = 1.00, Fig. 6; 5HT2C p = 0.22, data not shown). 
 
2.3.7.  Inflammatory status 
     Finally, levels of the inflammation transcription factor Nuclear Factor kappa-B (NFkB), 
and the inducible form of cyclo-oxygenase (COX-2), whose expression is usually linked to 
inflammation-induced oxidative stress, were examined. While there was no change in the 
levels of COX-2 in treated animals (p = 0.64), there was a significant increase in the 
expression of NFkB (p = 0.017) (data not shown). 
 
2.4   Effects of Ro61-8048 on cytokine levels 
     The administration of a foreign substance might induce an inflammatory response, and 
cytokines and chemokines can affect neuronal development. A sample of maternal blood 
was therefore collected into 20U/ml heparin by cardiac puncture 5h after the administration 
of Ro61-8048. Using Signosis ELISA profiling kits (Caltag Medsystems, Buckingham, UK) 
to measure cytokine levels in 6 animals showed no change in basal levels of interleukin-1 
(IL-1, p = 0.64), IL-1 (p = 0.59), IL-6 (p = 0.93), tumour necrosis factor- (TNF-; p = 
0.58), monocyte chemoattractant protein-1 (MCP-1; p = 0.17), macrophage inflammatory 
protein-1 (MIP-1; p = 0.51), Regulated on Activation, Normal T cell expressed and 
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secreted (RANTES) (p = 0.79) or interferon receptor (p = 0.79). These results exclude any 
interference by those inflammatory mediators in the changes observed here. 
 
 
3.  Discussion 
      The synthetic compound Ro61-8048 is one of the few substances known to inhibit 
selectively a central enzyme in the kynurenine pathway, KMO.  It is well documented that 
Ro61-8048 generates a shift in the ratio of kynurenic acid and quinolinic acid (Chiarugi et 
al., 2001; Chiarugi and Moroni, 1999; Rover et al., 1997; Cozzi et al., 1999) with increased 
tissue kynurenate (Rover et al., 1997) and extracellular dialysate levels of 10-fold or more 
(Urenjak and Obrenovitch, 2000). Nevertheless, since the metabolic status of animals is 
substantially altered in the later stages of gestation we felt it appropriate to confirm the 
activity of Ro61-8048 in our model. The compound was able to generate raised kynurenine 
and kynurenic acid levels within a few hours of administration and we propose that these 
changes are responsible for the protein and functional changes we have reported. The 
conventional view of the kynurenine pathway would predict that inhibition of KMO would 
also lead to a decreased concentration of quinolinic acid, but studies have repeatedly 
failed to show any alteration in quinolinic acid concentrations despite substantial increases 
in kynurenic acid levels (Chiarugi & Moroni, 1999;  Clark et al., 2005). This would suggest 
that quinolinic acid production can occur independently of KMO activity, possibly via an 
alternative, direct oxidation of anthranilic acid to 3-hydroxyanthranilic acid (Baran & 
Scwarcz 1990; Ueda et al.,1978). This scheme would be consistent with the dramatic 
increase in brain anthranilic acid concentrations we have reported in mice treated with 
Ro61-8048 (Clark et al., 2005). These factors emphasise our contention that the effects of 
Ro61-8048 reported here are more likely to be caused by increased kynurenic acid levels 
than to a decline in quinolinic acid production.” 
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    The 10-fold increases in kynurenine concentration produced by Ro61-8048 are 
generally greater than the 2-5-fold changes seen in a range of clinical conditions in 
humans (Chen & Guillemin 2009). However, there was no lasting effect of Ro61-8048 on 
the kynurenine pathway since the levels of tryptophan, kynurenine, kynurenic acid and 
anthranilic acid were normal by the age of P21. Thus, the molecular and functional 
changes we have observed at P21 are likely to be the result of interference with brain 
development over a relatively short period during gestation, resulting in changes in the 
absolute or relative amounts of developmentally relevant processes, or alterations in their 
rate of change during development.  
     It should be noted that fetal cells do express IDO so that tryptophan entering from the 
maternal circulation can be converted into kynurenine (Honig et al., 2004; Ligam et al. 
2005). In addition, IDO expression is high in the placenta itself and the kynurenine 
generated from its activity will cross the placental barrier readily into the fetus. 
     The results show that prenatal exposure to an inhibitor of KMO produces a range of 
significant molecular and physiological changes in the young offspring. NMDA receptors 
have well-established roles in the early migration of neural precursors, neuritogenesis, 
axonal guidance, spine formation and synapse formation (Colonnese et al., 2005; Komuro 
and Rakic, 1993; Behar et al., 1999; Heng et al., 1999; Cuppini et al., 1999; Rajan and 
Cline, 1998; Alvarez et al., 2007; Ultanir et al., 2007). Furthermore, NMDAR contribute to 
the programmed cell death which shapes the early nervous system by eliminating a 
proportion of neurons. Many of these same factors are involved in neuronal plasticity in the 
postnatal brain (Fagiolini et al., 2003; Iwasato et al., 2000). Indeed, it has been proposed 
that tissue formation and polarity may be determined largely by a gradient for a signal 
antagonist, such as kynurenic acid, rather than an agonist (Gurdon and Bourillot, 2001).     
     Perhaps the most surprising result from this work is the magnitude and selectivity of the 
changes in protein expression found in the embryonic brain 5h after exposure to Ro61-
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8048. None of the developmentally specific target molecules showed any change in their 
overall expression at this time, indicating no immediate change of guidance or contact 
processes and, most importantly, no direct effects of Ro61-8048 on the proteins examined. 
In contrast there were large, highly significant changes in the levels of the two NMDA 
receptor subunits GluN2A and GluN2B. In addition, the changes observed were in 
opposite directions, with a decreased level of GluN2A and increased GluN2B. The 
importance of this may lie in the requirement for a specific balance between these 
subunits, with a shift in their relative expression occurring progressively throughout 
development. The balance between these two subunits is critical in regulating neuronal 
function and early brain development (Brigman et al., 2010; McKay et al., 2012; Rammes 
et al., 2009)  as well as cell viability and degeneration (Hardingham and Bading, 2010). 
    By the time the newborn litter has reached 21 days of age, the situation is dramatically 
changed. The changes of NMDA receptor composition are still exclusively in the GluN2 
subunits, with no significant effects on the GluN1 subunits which contribute the crucial, 
universal element to all NMDAR. Although the GluN1 subunit is encoded by one gene, the 
protein is expressed as several splice variants. The antibody used in this work was 
selected as it interacts with all of the known splice variants, generating some confidence in 
the absence of any change in GluN1 expression. The continuing change in the expression 
of both GluN2 subunits, however, would produce significant overall changes in NMDAR 
function leading to alterations in neuronal development and function.  
     The electrophysiological analysis indicates an overall increase in neuronal excitability 
and altered synaptic function which is likely to result from a combination of altered 
neuronal development and the abnormal levels and ratio of GluN2 subunits. Slices from 
control and treated animals exhibited similar PPF across the range of interpulse intervals 
from 20 to 100ms. While PPI is usually attributed to the depletion of synaptic vesicles 
following the first stimulus (Rosenmund and Stevens, 1996; Wang and Kaczmarek, 
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1998), PPF is caused by the accumulation of calcium within synaptic terminals, leading to 
increased transmitter release and an increased size of the second potential of the pair 
(Zucker, 1989). The similar degrees of PPI and PPF, therefore, suggest no changes in 
either of these phenomena after Ro61-8048 exposure. 
     In contrast, changes were observed when paired-pulse interactions were examined at 
different frequencies of paired-pulse delivery. Increasing the frequency of stimulation from 
0.05 to 1Hz has been shown previously to induce a shift from PPF to PPI in the 
hippocampus (Saviane et al. 2002) and a similar shift can be induced by raising 
stimulation strength (Huang et al. 2007).  In the present study, increasing stimulation 
frequency converted PPF to PPI in control slices, whereas Ro61-8048-treated slices 
exhibited reduced PPF but no PPI, resulting in very significant differences between 
control and treated slices at presentation frequencies of 0.5Hz or greater.  
   Exposure to Ro61-8048 in utero led to an increase in the level of theta-burst-induced 
LTP with no change in the degree of LTD. The specificity of the phenomenon was 
emphasised by the absence of any significant difference in the amplitude of LTD. The 
occurrence of these various electrophysiological differences emphasise the ability of 
Ro61-8048 exposure in utero to generate significant changes in neuronal and synaptic 
function. The examination of protein expression was performed to identify some of the 
molecular changes that might contribute to this. 
 
3.1  Protein expression 
     In addition to the altered expression of GluN2 subunits, several of the 
neurodevelopmental proteins examined also exhibited marked changes.   The tyrosine 
kinase family of Eph receptors and their ephrin ligands are crucial to many aspects of 
neuronal development and synaptogenesis (Klein et al., 2004), and several of them 
modulate the activation of RhoGTPases. These molecules play similar and overlapping 
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roles, with EphA4 clearly linked to dendritic spine formation (Martinez and Soriano, 2005; 
Bourgin et al., 2007; Segura et al., 2007) and the formation of glutamatergic synapses 
(Aoto et al., 2007). The Eph receptors directly influence NMDAR function and may mediate 
the developmental and plastic consequences of activating NMDAR (Henderson et al., 
2001; Takasu et al., 2002). However, the present data indicate no significant change in the 
expression of EphA4, despite the significant changes in NMDA subunits, suggesting that 
the altered expression of NMDAR protein is not secondary to any change of EphA4 
expression. 
   A highly significant change was also seen in levels of RhoB.  The activation of glutamate 
receptors and their roles in synaptic plasticity are influenced by both the low molecular 
weight RhoGTPases RhoA and RhoB.  Li et al., (2002) were among the earliest to note an 
association between glutamate receptors and the activation of RhoGTPases, showing 
these enzymes mediated the effects of NMDA receptors on dendritic arborisation. This is 
probably dependent on the regulation of cytoskeletal components which determine cell 
polarity and motility as well as neuritogenesis (Narumiya et al., 1997; Luo, 2000). They are 
also likely to play a role in other neuronal responses to NMDA (Harris et al., 2003; 
Norenberg et al., 1999) including excitotoxicity and neuronal development (Koh et al., 
2006; Ahnert-Hilger et al., 2004; van Aelst and Cline, 2004). The two enzymes have 
different cellular localizations in the rat hippocampus and exhibit differential changes in 
response to electrical stimulation (O’Kane et al., 2003a,b; McNair et al., 2010). Activation 
of RhoA results in the suppression of synaptic plasticity, whereas RhoB enhances the 
extent of neuronal plasticity in response to the activation of NMDAR. The activation of 
RhoB was especially promoted by high frequency stimulation which induced NMDAR-
dependent LTP (O’Kane et al., 2003b). RhoA was not involved in this phenomenon. 
Consistent with this putative role for RhoB in NMDA receptor-dependent plasticity, 
inhibition of the target enzyme Rho-associated coiled coil protein kinase (ROCK) modified 
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the induction of LTP. The significant decrease in RhoB expression at P21, therefore, would 
be consistent with increased decreased amplitudes of LTP. 
     The inhibition of kynurenine metabolism yielded no changes in the presynaptic 
vesicular release proteins synaptophysin, synaptotagmin and synaptobrevin (VAMP-1). 
This negative result is especially interesting in view of reports that changes in the levels of 
synaptophysin and VAMP-1 occur in brain tissue from schizophrenic patients (Halim et al., 
2003; Maycox et al., 2009; Nadri and Agam, 2009). It is possible, however, that changes 
may have occurred before the P21 time point at which they were first examined in this 
study, since Afadlal et al (2010) reported that prenatal stress induced by maternal restraint 
or corticosterone injections produced a decrease in synaptophysin levels only in animals at 
P7 or P14, but not at later ages such as the P21, post-weaning time examined here.  
 
3.2  Neurogenesis 
    The nuclear protein PCNA is increasingly adopted as a marker for the early phases of 
cell generation in view of its function as a cofactor in the synthesis and repair of DNA (von 
Bohlen und Halbach, 2011). The significant increase in expression of PCNA therefore 
suggests a greater degree of neurogenesis in the brain at P21. This conclusion is strongly 
supported by the increased expression of doublecortin which has been linked to the later 
aspects of neurogenesis in the earliest stages of brain formation, being widely viewed as a 
marker of newly formed but immature or undifferentiated cells. The levels of doublecortin 
tend to diminish as brain development proceeds and neurogenesis decreases (von Bohlen 
und Halbach, 2011). The continuing presence of doublecortin in the mature CNS tends to 
be greatest in regions with the highest rates of neurogenesis, and its significant elevation 
in the experimental animals here would be consistent with a higher rate of new neuron 
formation and with the increased PCNA discussed above.  
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     Also consistent with this conclusion is the significantly increased expression of SHH, a 
protein known to be intimately involved in early tissue development, organization and 
orientation. SHH is expressed largely in fully differentiated neurons (Sims, 2009) and has 
most frequently been studied in relation to early cell proliferation and migration (Palma et 
al., 2005; Traiffort et al., 2001, 2010), although it has a major role to play in the mutual 
attraction between growing neurites and their targets both in nervous system development 
and in the early phases of regeneration after tissue injury (Hor and Tang, 2010; Angot et 
al., 2008; Traiffort et al., 2010). The change in SHH therefore may be a key factor in the 
altered expression of other proteins and in the functional changes demonstrated here. 
     
 
4. Materials and methods 
   This study was carried out according to the regulations of the Animals (Scientific 
Procedures) act 1986 of the UK, administered and monitored by the Home Office. Male 
and female Wistar rats were housed together for mating and inspected daily for the 
occurrence of a vaginal plug. The pregnant females were housed alone from that point, 
with free access to food and water.  
     In order to inhibit tryptophan oxidation along the kynurenine pathway (Fig. 1A) we have 
used 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulphonamide (Ro61-8048; 
Roever et al., 1997). This compound is an inhibitor of kynurenine-3-monoxygenase (KMO), 
a key enzyme in the pathway which shifts the balance of tryptophan metabolism such that 
the production of the NMDAR agonist, quinolinic acid, is reduced or the antagonist 
kynurenic acid is increased in vivo (Rover et al., 1997; Cozzi et al., 1999; Chiarugi and 
Moroni, 1999; Urenjak and Obrenovitch, 2000; Chiarugi et al., 2001; Clark et al., 2005; 
Gregoire et al., 2008) or in vitro (Carpenedo et al., 2002). From those earlier studies we 
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have already identified a dose of 100mg/kg (i.p.) as one which can be administered 
repeatedly to the same animal with few ill-effects in adult rats.  
   Results from two series of experiments are reported in this study. In one set, Ro61-8048 
was administered to pregnant dams on embryonic day E18, partly in order to demonstrate 
that this dose was sufficient to produce a significant change in the levels of kynurenic acid. 
An additional objective was to examine the immediate effects of Ro61-8048 on the levels 
of kynurenine metabolites and protein expression in the embryo brains measured after 5h 
and 24h.  
  In the second series of experiments, Ro61-8048 was administered to the pregnant dams 
on embryonic days E14, E16 and E18, after which gestation was allowed to proceed 
normally. The neonates were then euthanised on postnatal day 21 (P21), the day of 
weaning, for removal of the brain. Dams in the control groups were injected with vehicle 
only, administered in the same time schedule as the test compound. All tissue samples 
were frozen at -80C until analysis.  
 
4.1   High Pressure Liquid Chromatography (HPLC) 
   The High Performance Liquid Chromatography  (HPLC) system used for the 
analysis of the kynurenine pathway was modified from that used previously in this 
laboratory. In brief, L-kynurenine was quantified by absorbance detection spectrometry, 
while kynurenic acid levels were measured using fluorescence detection based on the 
original description by Hervé et al. (1996).   
During sample preparation, samples were kept on ice. To 250l plasma, 25l of 
internal standard (240M 3-nitro-L-tyrosine) and 25l 2M perchloric acid were added. 
Plasma samples were vortexed for 30s immediately after acid addition, centrifuged at 5000 
g for 10 minutes at 4°C, and the supernatant collected. Brain sample extracts were 
prepared by homogenising in 2 volumes (w/v) of 2M perchloric acid containing 3-nitro-L-
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tyrosine internal standard (240M). Homogenates were centrifuged at 10000 g for 10 
minutes at 4°C and the supernatant collected. All supernatants were then filtered in 
MicroSpin PVDF centrifuge tubes (Alltech, Carnforth, Lancashire, UK) using centrifugation 
at 10,000 g for 10 minutes at 4°C, prior to injection of 100l on to the HPLC column. 
Calibration curves were determined using various concentrations of standard compounds 
in solution.  
Isocratic reversed-phase HPLC was performed at 37°C, using a Waters HPLC 
system. For tryptophan, kynurenine and kynurenic acid determination, separation was 
achieved using a Synergi Hydro column (250 x 4.6mm I.D., particle size 4m;  
Phenomenex, Macclesfield, Cheshire, UK) and the detection system included both a 
Waters 2487 dual wavelength absorbance detector and a Waters 474 fluorescence 
detector, connected in series. The mobile phase was 50mM acetic acid, 100mM zinc 
acetate containing 1.5% acetonitrile using a flow rate of 1ml/min.  Zinc acetate was 
included in the mobile phase as it significantly enhances the fluorescence of kynurenic 
acid (Shibata, 1988). Tryptophan was determined by absorption spectrometry at a 
wavelength of 250nm and kynurenine was detected at 365nm. The internal standard, 3-
nitrotyrosine, was also quantified at 365nm. Fluorescence detection was used to quantify 
kynurenic acid (excitation 344nm, emission 390nm).   
The limits of detection using an injection volume of 100l and a signal-to-noise 
threshold of 3, were: tryptophan 20pmoles, kynurenine 1pmole and kynurenic acid 
0.2pmoles on column. Recoveries determined using samples spiked with standards of the 
measured compounds were between 90 and 110%.  
 
4.2  Electrophysiology 
     Electrophysiological studies were performed on male animals which were allowed to 
grow under normal conditions to 21 days of age (P21 animals). Animals were killed by 
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administration of an overdose of urethane (1.5g per rat delivered as an i.p. injection of a 
25% solution in water) followed by cervical dislocation. The brain was removed into ice-
cold artificial cerebrospinal fluid (aCSF) of composition: (in mM) NaCl 115; KH2PO4  2.2; 
KCl  2; MgSO4  1.2; NaHCO3 25; CaCl2 2.5; glucose 10, gassed with 5%CO2 in oxygen. 
The hippocampi were rapidly removed and chopped into 450m transverse slices using a 
McIlwain tissue chopper. The slices were preincubated at room temperature for at least 1 
hour in a water-saturated atmosphere of 5%CO2 in O2 before individual slices were 
transferred to a 1 ml capacity superfusion chamber for recording. Slices were superfused 
at 28-30C using aCSF at a flow rate of 3-4 ml/min. A concentric bipolar electrode was 
used for stimulation of the Schaffer collateral and commissural fibres in stratum radiatum, 
using stimuli delivered at 0.1 Hz or 0.05 Hz with a pulse width of 50-300 s, adjusted to 
evoke a response amplitude approximately 70% of maximum so as to allow increases or 
decreases in size to be detected. Extracellular recordings were made via glass 
microelectrodes containing 1M NaCl (tip diameter approximately 2m, DC resistances 2-
5M) with the tip positioned under microsopic visualisation in the stratum radiatum of the 
CA1 region to evoke field excitatory postsynaptic potentials (fEPSPs). Potentials were 
amplified, digitised and stored on computer via a CED (Cambridge Electronic Design, 
Cambridge, UK)) micro1401 interface. The fEPSPs were routinely quantified by 
measurement of the early positive-going slope of the potential, using Signal software 
(CED, Cambridge, UK). The axonal volley was monitored wherever it was possible to 
distinguish it clearly from the fEPSP in order to ensure that no change occurred during the 
experiments.  
     Once placed into the recording chamber, the recording of fEPSPs was allowed to 
stabilise and a minimum period of 10min obtained at a stable baseline. The degree of LTP 
and LTD was quantified by measuring the size of the evoked potentials once a post-
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stimulation plateau had been obtained and comparing with the potential size before 
stimulation.  
     Paired-pulse interactions were assessed using pairs of stimuli S1 and S2 with inter-
stimulus intervals of 10 -100ms. In the case of fEPSPs the 10ms interval resulted in a 
substantial overlap between successive potentials and an electronic subtraction was 
therefore performed (using Signal software, CED) in which a single evoked potential at 
time S1 was subtracted from a subsequent paired-pulse response to reveal the true 
magnitude of the response to S2. 
 
4.3  Immunoblotting 
    Brain sample homogenates were prepared in RIPA buffer (50mM Tris, 150mM NaCl, 
0.1% SDS, 0.5% Triton X-100, 1% IGEPAL, and a Roche complete protease inhibitor 
tablet) and centrifuged at 18000 g for 5 min at 4oC. Supernatants were collected for protein 
concentration determination using the Bio-Rad Coomassie Blue protein assay (Bio-Rad, 
Hemel Hempstead, UK). Samples were then normalised to 10g and prepared as; 65% 
protein sample, 25% sample buffer and 10% reducing agent (Life Technologies, Paisley, 
UK), and heated at 70oC for 10 min. The protein samples were loaded onto NuPAGE 
Novex 4-12% Bis-Tris (1.0mm) 15 lane gels (Life Technologies, Paisley, UK) and run at 
150 volts for 80 min to separate proteins according to their molecular weight. SeeBlue pre-
stained standard (Life Technologies, Paisley, UK) was included on each gel as a 
molecular weight marker. The separated proteins were then blotted onto Invitrolon 
poly(vinylidene difluoride) membranes (Life Technologies, Paisley, UK) at 30V for 60 min. 
The membranes were blocked for 1h in 5% non-fat dried milk solution in Tris-buffered 
saline containing 0.05% Tween (TBST), before overnight incubation at 4oC with the 
appropriate primary antibody (diluted in 5% milk-TBST). Membranes were then washed 3 
times for 15 min with TBST and incubated with the appropriate horseradish peroxidase 
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(HRP) conjugated secondary antibody (prepared in 5% milk-TBST) for 1h at room 
temperature. Following secondary antibody incubation, blots were washed 3 times for 15 
min with TBST then visualised using Enhanced Chemiluminescence Plus detection kit (GE 
Healthcare, Chalfont St Giles, UK).  
    Western blot analysis was carried out using the following primary antibodies:- PSD-95 
(rabbit monoclonal, 3450, 1 : 10000 dilution) (Cell Signalling, New England Biolabs, 
Hitchin, UK); DCC (mouse monoclonal, 554223, 1 : 5000 dilution) (BD Biosciences, 
Oxford, UK); GluN1 (mouse monoclonal, 05-432, 1 : 1000 dilution postnatal tissue, 1 : 500 
dilution embryonic tissue), tyrosine hydroxylase (mouse monoclonal, MAB5280, 1 : 10000 
dilution), synaptophysin (mouse monoclonal, MAB368, 1 : 40000 dilution) (Millipore, 
Watford, UK); GluN2A (rabbit polyclonal, PPS012, 1 : 5000 dilution postnatal tissue, 1 : 
1000 dilution embryonic tissue ), GluN2B (rabbit polyclonal, PPS013, 1 : 5000 dilution 
postnatal tissue, 1 : 1000 dilution embryonic tissue), VAMP-1/synaptobrevin (goat 
polyclonal, AF4828, 1 : 10000 dilution), synaptotagmin (MAB 43641, 1 : 5000 dilution) 
(RandD Systems, Abingdon, UK); RhoA (mouse monoclonal, sc-418, 1 : 1000 dilution), 
RhoB (mouse monoclonal, sc-8048, 1 : 1000 dilution), EphA4 (rabbit polyclonal, sc-921, 1 
: 5000 dilution), PCNA (mouse monoclonal, sc-56, 1 : 1000 dilution), Sox-2 (goat 
polyclonal, sc-17320, 1 : 250 dilution postnatal tissue, 1 : 1000 dilution embryonic tissue), 
5-HT2C (mouse monoclonal, sc-17797, 1 : 1000 dilution), NFkB (rabbit polyclonal, sc-372, 
1 : 5000 dilution postnatal tissue, 1 : 1000 embryonic tissue), COX-2 (goat polyclonal, sc-
1745, 1 : 1000 dilution), doublecortin (goat polyclonal, sc-8066, 1 : 1000 dilution postnatal 
tissue, 1 : 20000 dilution embryonic tissue), -synuclein (mouse monoclonal, sc-65500, 1 : 
1000 dilution), actin (goat polyclonal, sc-1615, 1 : 10000 dilution postnatal tissue, 1 : 
20000 dilution embryonic tissue), DISC1 (goat polyclonal, sc-47990, 1 : 1000 dilution 
postnatal tissue, 1 : 500 dilution embryonic tissue), Unc5H1 (goat polyclonal, sc-67902, 1 : 
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1000 dilution), Unc5H3 (goat polyclonal, sc-54442, 1 : 1000 dilution), SHH (goat 
polyclonal, sc-1194, 1 : 1000 dilution) (Santa Cruz, Insight Biotechnology, Wembley, UK). 
    The following secondary HRP-conjugated antibodies were used at 1 : 5000 dilution: 
goat anti-rabbit HRP (12-348) (Millipore, Watford, UK); donkey anti-goat HRP (sc-2020) 
and goat anti-mouse (sc-2005) (Santa Cruz, Insight Biotechnology, Wembley, UK) 
  
4.4  Data analysis and statistics 
   All western blots were quantified using the Image J software (http://rsb.info.nih.gov/ij/) 
and comparisons were made statistically between groups of pups born to mothers treated 
with Ro61-8048 and groups born to mothers injected with saline vehicle. This protocol 
allowed the use of unpaired t tests to examine differences between the two groups for the 
blots, cytokine ELISAs and HPLC data. In order to control for variations in the total amount 
of protein loaded onto gels, all samples were examined after staining with Ponceau S 
stain. In addition, actin levels were examined in each series of blots and the ratio taken of 
the intensity of target protein to the intensity of actin. For the parts of the 
electrophysiological analysis where indicated, data were analysed using analysis of 
variance followed by the Bonferroni multiple comparison test. A probability value of 
approximately 0.05 was adopted as the criterion for significance, although actual p-values 
are indicated when >0.0001. 
 
5.  Conclusion 
Prenatal inhibition of the kynurenine pathway alters the expression of several proteins 
key to early brain development, accompanied by changes of neuronal activity and 
synaptic transmission. Of the eight proteins whose expression is altered n P21 neonates, 
the majority are components of receptors, while PSD-95 forms part of the postsynaptic 
receptor NMDAR complex with associated proteins and plays a role in the membrane 
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stabilization and functional sensitivity of the NMDA receptor (Kornau et al., 1995; Rutter 
and Stephenson, 2000). RhoB proteins are elements of transduction pathways that 
regulate NMDAR function. Three of the proteins affected – doublecortin, PCNA and sonic 
hedgehog - are concerned with neuron formation and maturation. The results therefore 
indicate that activity in the endogenous oxidative metabolism of tryptophan along the 
kynurenine pathway is likely to play a fundamental role in the early development of the 
brain, probably by affecting the expression of NMDAR subunits and proteins that 
modulate NMDAR function. 
 
Acknowledgements 
We thank Epsom Medical Research, the Peacock Trust and the Haddon Family 
Foundation Trust for supporting this work. OSK was funded by a postgraduate scholarship 
in Integrative Biology (BBSRC) and MP was supported by the Malaysian Government 
 
 26 
REFERENCES 
 
Afadlal, S., Polaboon, N., Surakul, P., Govitrapong, P., Jutapakdeegul, N., 2010. Prenatal 
stress alters presynaptic marker proteins in the hippocampus of rat pups. Neurosci. Lett., 
470, 24-27. 
 
Ahnert-Hilger, G., Holtje, M., Grosse, G., Pickert, G., Mucke, C., Nixdorf-Bergweiler, B., 
Boquet, P., Hofmann, F., Just, I., 2004. Differential effects of Rho GTPases on axonal and 
dendritic development in hippocampal neurons. J. Neurochem., 90, 9 – 18. 
 
Alvarez, V.A.,  Ridenour, D.A., Sabatini, BL., 2007. Distinct structural and ionotropic roles 
of NMDA receptors in    controlling spine and synapse stability. J. Neurosci.,  27, 7365-
7376 
 
Angot, E., Loulier, K., Nguyen-Ba-Charvet, K.T., Gadeau, A.-P., Ruat, M., Traiffort, E. , 
2008. Chemoattractive activity of Sonic Hedgehog in the adult subventricular zone 
modulates the number of neural precursors reaching the olfactory bulb. Stem Cells, 26, 
2311-2320. 
 
Aoto, J., Ting, P., Maghsoodi, B., Xu, N.,  Henkemeyer, M., Chen, K., 2007. Postsynaptic 
EphrinB3 promotes shaft glutamatergic synapse formation. J. Neurosci., 27, 7508-7519.  
 
Baran, H., Schwarcz, R., 1990. Presence of 3-hydroxyanthranilic acid in rat-tissues and 
evidence for its production from anthranilic acid in the brain. J. Neurochem., 55, 738-744. 
 27 
 
Behar, T.N., Scott, C.A., Greene, C.L., Wen, X.L.,  Smith, S.V.,  Maric, D., Liu, Q.Y.,  
Colton, C.A, Barker, J.L ., 1999. Glutamate acting at NMDA receptors stimulates 
embryonic cortical neuronal migration. J. Neurosci.,  19, 4449-4461. 
 
Boegman, R.J., Eldefrawy, S.R., Jhamandas, K., Beninger, R.J., Ludwin, S.K., 1985. 
Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid. 
Neurobiol. Aging, 6, 331-336.  
 
Bourgin, C., Murai, K.K., Richter, M.& Pasquale, E.B., 2007. The EphA4 receptor regulates 
dendritic spine remodeling by affecting beta 1-integrin signaling pathways. J. Cell Biol., 
178, 1295-1307 
 
Brigman, J.L., Wright, T., Talani, G., Prasad-Mulcare, S., Jinde, S., Seabold, G.K., Mathur, 
P., Davis, M.I., Bock, R., Gustin, R.M., Colbran, R.J., Alvarez, V.A., Nakazawa, K., Delpire, 
E., Lovinger, D.M., Holmes, A., 2010. Loss of GluN2B-containing NMDA receptors in CA1 
hippocampus and cortex impairs long-term depression, reduces dendritic spine density, 
and disrupts learning. J. Neurosci., 30, 4590-4600. 
 
Carpenedo, R., Meli, E., Peruginelli, F., Pellegrini-Giampietro, D.E., Moroni, F., 2001. 
Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in 
organotypic hippocampal slice cultures. J. Neurochem., 82, 1465-1471.  
 
Chen, Y., Guillemin, G.J., 2009.  Kynurenine metabolism in humans: disease and healthy 
states. Intern. J. Tryptophan. Res., 2, 1-19. 
 
 28 
Chiarugi, A., Cozzi, A., Ballerini, C.,  Massacesi, L., Moroni, F., 2001. Kynurenine 3-mono-
oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of 
rats with experimental allergic encephalomyelitis. Neuroscience, 102, 687-695. 
 
Chiarugi, A., Moroni, F., 1999. Quinolinic acid formation in immune-activated mice: studies 
with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-
benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine 
hydroxylase. Neuropharmacology. 38, 1225-1233. 
 
Clark, C., Mackay, G.M., Smythe, G.A., Bustamante, S., Stone, T.W., Phillips, S.R., 2005. 
Prolonged survival of a murine model of cerebral malaria by kynurenine synthesis 
inhibition. Infection, Immunity 73, 5249-5251. 
 
Colonnese, M.T., Zhao, J.P., Constantine-Paton, M., 2005. NMDA receptor currents 
suppress synapse formation on sproutin axons in vivo. J. Neurosci.,  25, 1291-1303. 
.  
Cozzi, A., Carpenedo, R.,  Moroni, F., 1999. Kynurenine hydroxylase inhibitors reduce 
ischemic brain damage: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-
[-N-4-(nitrophenyl)thiazol-2YL]-benzenesulfonamide (Ro61-8048) in models of focal or 
global brain ischaemia. J. Cereb. Blood Flow Metab., 19, 771-777. 
 
Cuppini, R., Sartini, S., Ambrogini P, Falcieri, E., Maltarello, M.C., Gallo, G., 1999. Control 
of neuron outgrowth by NMDA receptors.  J. Submicrosc. Cytol. Pathol., 31, 31-40. 
 
Dikranian, K., Ishimaru MJ, Tenkova T, Labruyere, J., Qin, Y.Q., Ikonomidou, C., Olney, 
J.W., 2001. Apoptosis in the in vivo mammalian forebrain. Neurobiol. Dis., 8, 359-379.     
 29 
 
du Bois, T.M., Huang, X.F., 2007). Early brain development disruption from NMDA 
receptor hypofunction: relevance to schizophrenia. Brain Res. Rev., 53, 260-270. 
 
Fagiolini, M., Katagiri, H., Miyamoto, H., Mori, H., Grant, S.G.N., Mishina, M., Hensch, 
T.K., 2003. Separable features of visual cortical plasticity revealed by N-methyl-D-
aspartate receptor 2A signaling. Proc. Nat. Acad. Sci. U.S.A., 100, 2854-2859. 
 
Forrest, C.M., Addae, J.I., Murthy, S., Darlington, L.G., Morris, B.J., Stone, T.W., 2011. 
Molecular changes  associated with hippocampal long-lasting depression induced by the 
serine protease subtilisin-A. Europ. J. Neurosci., 34, 1241-1253 
 
Gregoire, L., Rassoulpour, A., Guidetti, P., Samadi, P., Bedard, P J.,  Izzo, Ea., Schwarcz, 
R.,  Di Paolo, T., 2008. Prolonged kynurenine 3-hydroxylase inhibition reduces 
development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain 
Res., 186, 161-167. 
 
Gurdon, J.B., Bourillot, P.Y., 2001. Morphogen gradient interpretation. Nature, 413, 797-
803. 
 
Halim, N.D., Weickert, C.S., McClintock, B.W., Hyde, T.M., Weinberger, D.R., Kleinman, 
J,E., Lipska, B.K., 2003. Presynaptic proteins in the prefrontal cortex of patients with 
schizophrenia and rats with abnormal prefrontal development. Molec. Psychiat., 8, 797-
810. 
 
 30 
Hardingham, G.E., Bading, H., 2010. Synaptic versus extrasynaptic NMDA receptor 
signalling: implications for neurodegenerative disorders. Nature Rev. Neurosci., 11, 682-
696. 
 
Harris, L.W., Sharp, T., Gartlon, J., Jones, D.N.C., Harrison, P.J., 2003. Long-term 
behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. 
Europ. J. Neurosci., 18, 1706-1710.  
 
Henderson, J.T., Georgiou, J., Jia, Z.P., Robertson, J., Elowe, S., Roder, J.C., Pawson, T., 
2001. The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function 
Neuron, 32, 1041-1056 
 
Heng, J.E., Zurakowski, D., Vorwerk, C.K., Grosskreutz, C.L., Dreyer, E.B., 1999. Cation 
channel control of neurite morphology. Develop. Brain Res., 113, 67-73 
 
Herve, C., Beyne, P., Jamault, H., Delacoux, E., 1996. Determination of tryptophan and its 
kynurenine pathway metabolites in human serum by high-performance liquid 
chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr B., 
675, 157-161. 
 
Hilmas, C., Pereira, E.F.R., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, 
E.X. , 2001. The brain metabolite kynurenic acid inhibits alpha 7 nicotinic receptor activity 
and increases non-alpha 7 nicotinic receptor expression:  physiopathological implications 
J. Neurosci.,  21, 7463-7473. 
 
 31 
Honig, A., Rieger, L., Kapp, M., Sutterlin, M., Dietl, J., Kammerer, U., 2004. Indoleamine 
2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the 
enzyme for materno-fetal tolerance. J. Reprod. Immunol., 61, 79-86. 
 
Hor, C.H.H., Tang, B.L., 2010). Sonic hedgehog as a chemoattractant for adult NPCs. Cell 
Adhesion and Migration, 4, 1-3. 
 
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vockler, J., Dikranian, K., Tenkova, T.I., 
Stefovska, V., Turski, L., Olney, J.W., 1999. Blockade of NMDA receptors and apoptotic 
neurodegeneration in the developing brain. Science, 283, 70-74. 
 
Iwasato, T., Datwani, A., Wolf, A.M., Nishiyama, H., Taguchi, Y., Tonegawa, S., Knopfel, 
T., Erzurumlu, R.S., Itohara, S., 2000. Cortex-restricted disruption of NMDAR1 impairs 
neuronal patterns in the barrel cortex. Nature, 406, 726-731. 
 
Klein, R., 2004. Eph/ephrin signaling in morphogenesis, neural development and plasticity.  
Curr. Opin. Cell. Biol., 16,580-589. 
 
Koh, C.-G., 2006. RhoGTPases and their regulators in neuronal function and 
development. Neurosignals, 15, 228-237. 
 
Komuro, H., Rakic, P., 1993. Modulation of neuronal migration by NMDA receptors. 
Science, 260, 95-97. 
 
 32 
Kornau, H.C., Schenker, L.T., Kennedy, M.B., Seeburg, P.H., 1995. Domain interaction 
between NMDA receptor subunits and the postsynaptic density protein PSD-95. 
Science, 269, 1737-1740. 
 
Larson, J., Wong, D.L., Lynch, G., 1986. Patterned stimulation at the theta frequency is 
optimal for the induction of hippocampal long-term potentiation. Brain Res., 368, 347-350. 
 
Li, Z., Aizenman, C.D., Cline, H.T., 2002. Regulation  of RhoGTPases by crosstalk and 
neuronal activity in vivo. Neuron, 33, 741-750. 
 
Ligam, P., Manuelpillai, U., Wallace, E.M., Walker, D., 2005. Localisation of indoleamine 
2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: 
Implications for role of the kynurenine pathway in pregnancy.  Placenta, 26, 498-504. 
 
Luo, L.Q., 2000. RhoGTPases in neuronal morphogenesis. Nature Revs. Neurosci., 1, 
173-180. 
 
Martinez, A,, Soriano, E., 2005. Functions of ephrin/Eph interactions in the development of 
the nervous system: Emphasis on the hippocampal system. Brain Res. Revs., 49, 211-
226. 
 
Maycox, P. R., Kelly, F., Taylor, A., Bates, S., Reid, J., Logendra, R., Barnes, M. R., 
Larminie, C., Jones, N., Lennon, M., Davies,T.I., Hagan, J. J., Scorer, C.A., Angelinetta, 
C., Akbar, T., Hirsch, S., Mortimer, A. M., Barnes, T. R. E., de Belleroche, J., 2009. 
Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes 
associated with nerve terminal function. Molec. Psychiat., 14, 1083-1094. 
 33 
 
McKay, S. Griffiths, N.H., Butters, P.A., Thubron, E.B., Hardingham, G.E., Wyllie, D.J.A., 
2012. Direct pharmacological monitoring of the developmental switch in NMDA receptor 
subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. 
Brit. J. Pharmacol., 166, 924-937. 
 
McNair, K., Spike. R., Guilding, C., Prendergast, G.C., Stone, T.W., Cobb, S.R., Morris, 
B.J., 2010. A role for RhoB in synaptic plasticity and the regulation of neuronal 
morphology. J. Neurosci., 30, 3508-3517. 
 
Nadri, C., Agam, G., 2009. Perinatal oxygen restriction does not result in reduced rat 
frontal cortex: synaptophysin levels at adulthood as opposed to postmortem findings in 
schizophrenia. J. Molec. Neurosci., 37, 60-66. 
 
Narumiya, S., Ishizaki, T., Watanabe, N., 1997. Rho effectors and reorganization of actin 
cytoskeleton. FEBS Lett., 410, 68-72. 
 
Norenberg, W., Hofmann, F., Illes, P., Aktories, K., Meyer, DK., 1999. Rundown of 
somatodendritic N-methyl-D-aspartate (NMDA) receptor channels in rat hippocampal 
neurones: evidence for a role of the small GTPase RhoA. Brit. J. Pharmacol., 127, 1060-
1063. 
 
O'Kane, E.M., Stone, T.W., Morris, B.J., 2003a. Activation of Rho GTPases by synaptic 
transmission in the hippocampus. J. Neurochem., 87, 1309-1312  
 34 
 
O'Kane, E.M., Stone, T.W., Morris, B.J., 2003b. Distribution of Rho family GTPases in the 
adult rat hippocampus and cerebellum. Molec Brain Res., 114: 1-8  
 
Palma, V., Lim, D.A., Dahmane, N., Sanchez, P., Brlonne, T.C., Herzberg, C.D., Gitton, Y., 
Carleton, A., Alvarez-Buylla, A., Altaba, A.R.I., 2005. Sonic hedgehog controls stem cell 
behavior in the postnatal and adult brain. Development, 132, 335-344. 
 
Perkins, M.N., Stone, T.W., 1982. An iontophoretic investigation of the action of convulsant 
kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res., 
247, 184-187 
 
Poulaki, V., Benekou, A, Bozas E, Bolaris, S., Stylianopoulou, F., 1999. P53 expression 
and regulation by NMDA receptors in the developing rat brain. J. Neurosci. Res.,  56, 427-
440. 
 
Rajan I,, Cline, H.T., 1998. Glutamate receptor activity is required for normal development 
of tectal cells dendrites in vivo. J. Neurosci., 18, 7836-7846. 
 
Rammes, G. Starker, L.K., Haseneder, R., Berkmann, J., Plack, A., Zieglgansberger, W., 
Ohl, F., Kochs, E.F., Blobner, M., 2009. Isoflurane anaesthesia reversibly improves 
cognitive function and   long-term potentiation (LTP) via an up-regulation in NMDA 
receptor 2B   subunit expression. Neuropharmacology, 56, 626-636. 
 
 35 
Rodgers, J., Stone, T.W., Barratt, M.P., Bradley, B., Kennedy, P.G., 2009. Kynurenine 
pathway inhibition reduces central nervous system inflammation in a model of human 
African trypanosomiasis. Brain 132, 1259-1267. 
 
Rosenmund, C., Stevens, C.F., 1996. Definition of the readily releasable pool of vesicles 
at hippocampal synapses. Neuron, 16, 1197-1207. 
 
Rover, S., Cesura, A.M., Huguenin, P., Kettler, R., Szente, A., 1997. Synthesis and 
biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity 
inhibitors of kynurenine 3-hydroxylase. J. Med. Chem., 40, 4378-4385. 
 
Rutter, A.R., Stephenson, F.A., 2000.  Coexpression of postsynaptic density-95 protein 
with NMDA receptors results in enhanced receptor expression together with a decreased 
sensitivity to L-glutamate. J. Neurochem.,  75, 2501-2510. 
 
Saviane, C., Savtchenko, L.P., Raffaelli, G., Voronin, L.L, Cherubini. E., 2002. Frequency-
dependent shift from paired-pulse facilitation to paired-pulse depression at unitary CA3-
CA3 synapses in the rat hippocampus. J. Physiol.(Lond.), 544, 469-476. 
 
 Scharfman, H.E., Hodgkins, P.S., Lee, S.C., Schwarcz, R., 1999. Quantitative differences 
in the effects of de novo produced and    exogenous kynurenic acid in rat brain slices. 
Neurosci. Lett.,  274, 111-114. 
 
Segura, I., Essmann, C.L.,Weinges, S., Acker-Palmer, A.(2007. Grb4 and GIT1 transduce 
ephrinB reverse signals modulating spine morphogenesis and synapse formation.  Nature 
Neurosci., 10, 301-310. 
 36 
 
Shibata, K., 1988. Fluorimetric micro-determination of kynurenic acid, an endogenous    
blocker of neurotoxicity, by high-performance liquid-chromatography. 430, 376-380. 
 
Sims, J.R., Lee, S.W., Topalkara, K., Qiu, J., Xu, J.,Zhou, Z., Moskowitz, M.A., 2009. 
Sonic hedgehog regulates ischemia/hypoxia-induced neural progenitor proliferation. 
Stroke, 40, 3618-3626. 
 
Stone, T.W., 1993. The neuropharmacology of quinolinic and kynurenic acids.  Pharmacol. 
Revs., 45, 309-379. 
 
Stone, T.W., 2001. Kynurenines in the CNS - from obscurity to therapeutic importance. 
Progr. Neurobiol., 64, 185-218 
 
Stone, T.W., 2007. Kynurenic acid blocks nicotinic synaptic transmission to hippocampal 
interneurons  in young rats. Europ. J. Neurosci., 25, 2656 – 2665  
 
Stone, T.W., Darlington, L.G., 2002. Endogenous kynurenines as targets for drug 
discovery and development. Nature Revs. Drug Disc., 1, 609-620. 
 
Stone, T.W., Perkins, M.N., 1981. Quinolinic acid: a potent endogenous excitant at amino 
acid receptors in CNS. Europ. J. Pharmacol., 72, 411-412. 
 
Takasu, M.A., Dalva, M.B., Zigmond, R.E., Greenberg, M.E., 2002. Modulation of NMDA 
receptor-dependent calcium influx and gene expression through EphB receptors. Science, 
295, 491-494.   
 37 
 
Traiffort, E., Moya, K.L., Faure, H., Hassig, R., Ruat, M., 2001. High expression and 
anterograde axonal transport of aminoterminal sonic hedgehog in the adult hamster brain. 
Europ. J. Neurosci., 14, 839-850. 
 
Traiffort, E., Angot, E., Ruat, M., 2010. Sonic hedgehog in the mammalian brain. J. 
Neurochem., 113, 576-590. 
 
Ueda, T., Otsuka, H., Goda, K., Ishiguro, I., Naito, J., Kotake, Y., 1978. Metabolism of 
[carboxyl-C-14]-anthranilic acid .1. incorporation of radioactivity into NAD+ and NADP+. J. 
Biochem. 84, 687-696 
 
Ultanir, S.K.,  Kim, J.E., Hall, B.J., Deerinck, T., Ellisman, M., Ghosh, A., 2007. Regulation 
of spine morphology and spine density by NMDA receptor signaling in vivo. Proc. Nat. 
Acad. Sci. U.S.A., 104, 19553-19558.  
 
Urenjak, J., Obrenovitch, T.P., 2000). Kynurenine 3-hydroxylase inhibition in rats: Effects 
on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced 
depolarisation in the striatum. J. Neurochem., 75, 2427-2433. 
 
Van Aelst, L., Cline, H.T., 2004. RhoGTPases and activity-dependent dendrite 
development. Curr. Opin. Neurobiol., 14, 297-304. 
 
Von Bohlen und Halbach, O., 2011. Immunohistological markers for proliferative events, 
gliogenesis and neurogenesis within the adult hippocampus. Cell Tiss. Res., 2011, 345,1-
19. 
 38 
 
Waldeck, R.F., Pereda, A., Faber, D.S., 2000. Properties and plasticity of paired-pulse 
depression at a central synapse. J. Neurosci., 20, 5312-5320. 
 
Wang, L.Y., Kaczmarek, L.K., 1998. High-frequency firing helps replenish the readily 
releasable pool of synaptic vesicles. Nature, 394, 384-388. 
 
Zucker, R.S., 1989. Short-term synaptic plasticity. Ann. Rev. Neurosci. 12, 13-31. 
 
Zwilling, D., Huang, S.Y., Sathyasaikumar, K.V., Notarangelo, F.M., Guidetti, P., Wu, H.Q., 
Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E.W., Louie, J.Y., Wu, T., Scearce-Levie, 
K., Patrick, C., Adame, A., Giorgini, F., Moussaoui, S., Laue, G., Rassoulpour, A., Flik, G., 
Huang, Y., Muchowski, J.M., Masliah, E., Schwarcz, R.,  Muchowski, P.J., 2011. 
Kynurenine 3-Monooxygenase inhibition in blood ameliorates Neurodegeneration. Cell, 
145, 863-874. 
 
 
 39 
Figure legends 
 
Figure 1.    HPLC analysis of tryptophan metabolites after the administration of 
Ro61-8048. 
A. Major components of the kynurenine pathway. The enzyme kynurenine-3-
monoxygenase (KMO) converts kynurenine into 3-hydroxykynurenine. Inhibition of this 
enzyme by Ro61-8048 forces the transamination of kynurenine to kynurenic acid via 
kynurenine aminotransferase.  
B. Bar charts showing the kynurenine pathway metabolite levels detected by High 
Performance Liquid Chromatography (HPLC) 5h following a single maternal injection of 
Ro61-8048 (R) or saline vehicle (S) on embryonic day 18 (E18). Panels summarise (a) the 
maternal plasma levels (M) or brain concentrations in the mother (b,c) and embryos (d,e) 
(per gramme wet weight; g.w.w.) of kynurenine and kynurenic acid 5h (b,d) and 24h (c,e) 
after the administration of Ro61-8048. Bars indicate mean ± s.e.mean for maternal plasma 
and brain samples (n=3) from 3 separate litters, or embryo brain samples (n=6) where 2 
embryo brains/litter were analysed from each of the 3 litters.  
* P < 0.05; ** P < 0.01; ***P < 0.001 unpaired t test. 
 
 
Figure 2.     Protein expression in the brain of embryos after prenatal Ro61-8048. 
Bar charts showing the quantified expression of (A) GluN2A (180kDa) and GluN2B 
(180kDa) proteins in the brains of embryos 5h after the prenatal administration of Ro61-
8048, while (B) shows the expression of sonic hedgehog (SHH, 45kDa) and NFkB (65kDa) 
at 24h post-administration. The bars indicate the mean  s.e.mean (n = 6) in arbitrary units 
of optical density (OD) expressed as the ratio of test protein to actin. Representative 
western blots above each chart illustrate the data obtained from animals exposed to the 
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saline vehicle (S) or Ro61-8048 (R) and show the relevant protein and the corresponding 
actin (42kDa) blot used as a housekeeping marker.    * P < 0.05; ** P < 0.01 unpaired t 
test. 
 
 
Figure 3.  Hippocampal function in P21 offspring after prenatal Ro61-8048.  
The graphs show the increase in size of (A) field excitatory postsynaptic potentials 
(fEPSPs) and (B) population spikes in the hippocampal CA1 region as a function of 
stimulus current, which was increased from threshold in steps of 5A (A) or 10A (B). The 
inset of panel (A) illustrates sample fEPSPs for a typical slice. Ordinate values are 
expressed in (A) relative to the maximum fEPSP obtained before any appearance of a 
population spike, and in (B) relative to the maximum population spike amplitude 
obtainable.  The symbols indicate mean  s.e.mean (n = 16 controls and 15 treated) for 
animals exposed to saline vehicle (solid circles) or Ro61-8048 (open circles). 
Paired-pulse data are shown for the ratio of fEPSPs recorded in stratum radiatum 
produced by each of the two paired stimuli (C), and the ratio of population spikes recorded 
in stratum pyramidale (D). The change in population spike ratio at different rates of paired-
pulse presentation from 0.05 to 1Hz is shown in (E) The symbols indicate mean  
s.e.mean (n = 10 controls and 12 treated) for animals exposed to saline vehicle (solid 
circles) or Ro61-8048 (open circles). 
* P < 0.05; ** P < 0.01; ***P < 0.001 using the Bonferroni test for multiple comparisons 
following ANOVA (P < 0.0001, see text). Number of samples is indicated above. 
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Figure 4. Adult hippocampal plasticity after prenatal exposure to Ro61-8048.  
Panel (A) illustrates long-term potentiation in the two groups of offspring following theta-
burst stimulation at the arrow. The inset records illustrate a control fEPSP immediately 
before stimulation and the potentiated response 40min later in a slice from a control animal 
(B) or an animal exposed in utero to Ro61-8048 (C). 
The symbols indicate mean  s.e.mean (n = 6). Calibrations 0.5mV and 10ms. 
*** P < 0.001 for the final 5 minutes of recording (ANOVA). 
Panel (D) illustrates long-term depression in the two groups of offspring induced by two 
periods of low frequency stimulation indicated by the bars on the abscissa at stim1 and 
stim2 (see text). The inset records illustrate a control fEPSP immediately before stim1 and 
the depressed responses 20min after stim1 and 20 min after stim2 in a slice from a control 
animal (E) or an animal exposed in utero to Ro61-8048 (F). 
The symbols indicate mean  s.e.mean (n = 6). There were no significant differences 
between the control and treated slices. 
Calibrations 1mV, 10ms for the control records and 0.5mV, 10ms for drug-exposed slices.  
 
Figure 5.  Protein expression in the brains of P21 offspring after prenatal Ro61-8048. 
Bar charts showing the quantified expression of GluN1 (130kDa), GluN2A (180kDa), 
GluN2B (180kDa), PSD-95 (95kDa), RhoA (24kDa) and RhoB (25kDa) proteins in the 
brains of P21 offspring following their prenatal exposure to Ro61-8048.  The bars indicate 
the mean  s.e.mean (n = 6) in arbitrary units of optical density (OD) expressed as the 
ratio of test protein to actin. Representative western blots above each chart illustrate the 
data obtained from animals exposed to the saline vehicle (S) or Ro61-8048 (R) and show 
the relevant protein and the corresponding actin (42kDa) blot used as a housekeeping 
marker.   * P < 0.05; ** P < 0.01 unpaired t test. 
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Figure 6.     Protein expression in the brains of P21 offspring after prenatal Ro61-
8048. 
Bar charts showing the quantified expression of PCNA (36kDa), doublecortin (40kDa), 
sonic hedgehog (SHH, 45kDa), tyrosine hydroxylase (TH, 60kDa), -synuclein (19kDa) 
and DISC1 (100kDa) proteins in the brains of P21 offspring following their prenatal 
exposure to Ro61-8048.  The bars indicate the mean  s.e.mean (n = 6) in arbitrary units 
of optical density (OD) expressed as the ratio of test protein to actin. Representative 
western blots above each chart illustrate the data obtained from animals exposed to the 
saline vehicle (S) or Ro61-8048 (R) and show the relevant protein and the corresponding 
actin (42kDa) blot used as a housekeeping marker.  
* P < 0.05 unpaired t test. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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